ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Scleroderma"

  • Abstract Number: 0942 • ACR Convergence 2023

    G Protein-coupled Receptor Kinase 5 in Fibrotic Tissue Remodeling

    Cuong Tran-Manh1, Thuong Trinh-Minh1, Christoph Liebel1, Chih-Wei Chen2 and Joerg Distler1, 1Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, 23 Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany. 4 Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany

    Background/Purpose: G-protein coupled receptor kinase 5, GRK5, is a central regulator of G protein-coupled receptors (GPCRs), a vast family of cell surface receptors involved in…
  • Abstract Number: 1524 • ACR Convergence 2023

    The Effectiveness of Nintedanib in Treating Fibrosing Interstitial Lung Disease in Both Scleroderma and Non-scleroderma Patients: A Systematic Review and Meta-analysis

    Yasmin Khader, Fatima Rawish, Aya Abughrbyeh, Samantha Davis, Sabeen Sidiki, Pejma Safavi and Nezam Altorok, University of Toledo, Toledo, OH

    Background/Purpose: Nintedanib, an intracellular inhibitor of tyrosine kinases, has shown promise in clinical trials by inhibiting key processes associated with the advancement of lung fibrosis.…
  • Abstract Number: 2366 • ACR Convergence 2023

    Spatial Frequency Domain Imaging as a Novel Method to Quantify Longitudinal Skin Changes in Scleroderma

    Hung Vo1, Aarohi Mehendale2, Anahita Pilvar3, Eugene Kissin4, Marcin Trojanowski5, Michael York6, Darren Roblyer2 and Andreea Bujor6, 1Boston Medical Center, Peabody, MA, 2Department of Biomedical Engineering, Boston University, Boston, MA, 3Department of Electrical and Computer Engineering, Boston University, Boston, MA, 4Boston University, Newton, MA, 5Boston University School of Medicine, Boston, MA, 6Boston University, Boston, MA

    Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by excessive collagen deposition in the skin and internal organs, along with vascular dysfunction. The modified…
  • Abstract Number: 0093 • ACR Convergence 2023

    Single Cell RNA-seq and Mass Cytometry Reveal a Cytotoxic CD8 Effector T Cell Population Associated with Interstitial Lung Disease in Systemic Sclerosis Patients

    Ye Cao1, Takanori Sasaki2, Richard Ainsworth3, Kim Taylor4, Nunzio Bottini5, Mehreen Elahee6, Edy Kim7, Francesco Boin3 and Deepak Rao7, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 3Cedars-Sinai Medical Center, Los Angeles, CA, 4University of California San Francisco, San Francisco, CA, 5University of California, San Francisco, CA, 6University of Pittsburgh Medical Center, Pittsburgh, PA, 7Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in systemic sclerosis (SSc). We aimed to identify features of circulating immune…
  • Abstract Number: 0639 • ACR Convergence 2023

    Evaluating Esophageal Dysmotility by Scintigraphy in Systemic Sclerosis: Subsets and Phenotypes

    Antonio Salas1, Lisa Yanek2 and Zsuzsanna McMahan3, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University School of Medicine Department of Medicine, Baltimore, MD, 3Johns Hopkins Rheumatology, Lutherville, MD

    Background/Purpose: Gastrointestinal (GI) dysmotility affects most patients with systemic sclerosis (SSc), and the esophagus is the most commonly affected region. While most SSc patients are…
  • Abstract Number: 0944 • ACR Convergence 2023

    Macrophages Regulate Adipocyte Differentiation and Proliferation in Skin Fibrosis

    Chanhyuk Park, Helen Jarnagin, Michael Whitfield and Patricia Pioli, Geisel School of Medicine at Dartmouth, Hanover, NH

    Background/Purpose: Autoimmune systemic sclerosis (SSc) is characterized by inflammation, vasculopathy, and dermal and internal organ fibrosis.  A widely-reported but poorly understood aspect of SSc skin…
  • Abstract Number: 1527 • ACR Convergence 2023

    Acute Effects of Intravenous Iloprost on Finger Power Doppler Ultrasound in Scleroderma Patients

    Sofia Testoni1, Luca Magnani2, Caterina Tomassini3, Alessia Laneri3, Carlo Salvarani4 and PIERLUIGI MACCHIONI2, 1Università degli Studi di Modena e Reggio Emilia, San Giovanni in Persiceto, Italy, 2Azienda USL -IRCCS di Reggio Emilia, Reggio Emilia, Italy, 3Università degli Studi di Modena e Reggio Emilia, Modena, Italy, 4Azienda USL -IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy

    Background/Purpose: So far few studies explored ultrasound (US) as a tool to assess vascular subcutaneous involvement in patients affected by systemic sclerosis (SSc). We aim…
  • Abstract Number: 2368 • ACR Convergence 2023

    Is Skin Disease a Local Manifestation of Systemic Tissue Turnover? Serological Collagen Biomarkers Provide Important Information on Skin Diseases Arising from Mutations in Collagen Genes

    Signe Holm Nielsen1, Matej Anđelić2, Dovile Sinkeviciute1, Anne-Christine Bay-Jensen1 and Morten Karsdal1, 1Nordic Bioscience, Herlev, Denmark, 2Nordic Bioscience, Copenhagen, Denmark

    Background/Purpose: Collagens are the main constituents of the skin. Genetic mutations in type VI, VII, and XVII collagen cause skin diseases, such as atopic dermatitis,…
  • Abstract Number: 029 • 2023 Pediatric Rheumatology Symposium

    Cardiac Magnetic Resonance Imaging in Children with Systemic Lupus Erythematosus and Scleroderma Spectrum Disorders: A Single Center Experience

    Meredith Rae, Tam Doan and Eyal Muscal, Baylor College of Medicine, Houston, TX

    Background/Purpose: Cardiac disease is a major cause of morbidity and mortality in children with SLE and SSc. Various studies have demonstrated an association between duration…
  • Abstract Number: 086 • 2023 Pediatric Rheumatology Symposium

    Systemic Sclerosis Overlap Syndrome: A Case Series from a Single Large Pediatric Center

    Jessica Nguyen1, Miriah Gillispie-Taylor1, Eyal Muscal1 and Marietta Deguzman2, 1Baylor College of Medicine, Houston, TX, 2Baylor College of Medicine, Texas Children's Hospital, Houston, TX

    Background/Purpose: Childhood-onset systemic sclerosis (SSc) is a rare but potentially life-threatening autoimmune condition with features including immune, fibrotic, and vascular manifestations affecting the skin and…
  • Abstract Number: 098 • 2023 Pediatric Rheumatology Symposium

    Characterization of Pulmonary Nodules in Juvenile-onset Systemic Sclerosis: A Single Center Case-Series

    Jonathan Li1, Franziska Rosser1, Sameh Tadros1 and Kathryn Torok2, 1UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Given the high prevalence of intestinal lung disease (ILD) in systemic sclerosis (SSc) and the low sensitivity of pulmonary function testing for diagnosing ILD,…
  • Abstract Number: 116 • 2023 Pediatric Rheumatology Symposium

    Clinical Significance of Anti-Scl-70 Antibodies in Pediatric Lupus Patients: A Single Center Cohort

    Dawn Janysek1, Yiressy Pina2, Danielle Guffey3 and Marietta De Guzman1, 1Baylor College of Medicine, Texas Children's Hospital, Houston, TX, 2Baylor College of Medicine, Texas Children's Hospital, Houston, TX, 3Baylor College of Medicine, Houston, TX

    Background/Purpose: Production of autoantibodies is a hallmark of SLE, with ANAs as a required diagnostic feature and anti-dsDNA and anti-Smith antibodies being disease-specific. Anti-Scl-70 antibodies…
  • Abstract Number: 123 • 2023 Pediatric Rheumatology Symposium

    Development of Specific Classification Criteria for Juvenile System Sclerosis Patients: A Scoping Review

    Ioana Dobre1, Suzanne Li2, Natalia Vasquez Canizares3, Barbara Reich4, Xurong Zhao5, Quinn McCormick6 and Marinka Twilt5, 1Alberta Children's Hospital/University of Calgary, Calgary, AB, Canada, 2Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, Hackensack, NJ, 3Children's Hospital at Montefiore, New York, NY, 4Hackensack University Medical Center, Hackensack, NJ, 5Alberta Children's Hospital, Calgary, AB, Canada, 6Hackensack Medical Hospital Network, Hackensack, NJ

    Background/Purpose: Juvenile systemic sclerosis (jSSc) is associated with one of the highest morbidity and mortality rate in pediatric rheumatology, yet care recommendations are based upon…
  • Abstract Number: 0712 • ACR Convergence 2022

    Disease Prevalence and Patient Characteristics in Patients with and Without Scleroderma Renal Crisis – A National US-based Inpatient Comparison Study

    Anila Hussain1, Pushti Khandwala2 and Thais Moldovan3, 1Crozer Chester Medical Center, Glen Mills, PA, 2Einstein Medical Center Philadelphia, Glen Mills, PA, 3Rheumatology Care Center, Media, PA

    Background/Purpose: Scleroderma renal crisis is a rare complication of Systemic Sclerosis (SSc) with high mortality and morbidity. Most patients present with acute symptomatic increase in…
  • Abstract Number: 1170 • ACR Convergence 2022

    Systemic Sclerosis Dermal Fibroblast-derived Exosomes Trigger a Type 1 Interferon Rresponse in Keratinocytes Through TBK1

    Jessica Bryon1, Christopher Wasson1, Rebecca Ross1, Elton Zeqiraj1 and Francesco Del Galdo2, 1University of Leeds, Leeds, United Kingdom, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health and NIHR Biomedical Research Centre, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Elevated Type I IFN response is present in blood and affected tissues in systemic sclerosis (SSc) and correlates with disease activity and response to…
  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 33
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology